Search Result

Results for "

LT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (3) Apoptosis (5) Bacterial (1) c-Myc (2) Caspase (1) CCR (1) CDK (2) COX (3) CXCR (1) Dengue Virus (1) EGFR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) Epoxide Hydrolase (2) FLAP (5) Flavivirus (1) FLT3 (5) Fluorescent Dye (2) G protein-coupled Bile Acid Receptor 1 (1) HDAC (1) Histone Methyltransferase (1) Insecticide (1) Integrin (1) Interleukin Related (4) IRAK (1) Isotope-Labeled Compounds (3) JNK (1) KLF (1) Leukotriene Receptor (6) Ligands for Target Protein for PROTAC (1) LPL Receptor (3) NF-κB (4) NO Synthase (2) NOD-like Receptor (NLR) (1) P-selectin (1) p38 MAPK (1) Parasite (1) PARP (5) Phosphodiesterase (PDE) (1) Phospholipase (1) PPAR (1) PROTACs (1) Pyroptosis (1) Reference Standards (2) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (2) TNF Receptor (4) Transferrin Receptor (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (2) Endocrinology (1) Infection (2) Inflammation/Immunology (27) Metabolic Disease (6) Neurological Disease (4)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16106

Talazoparib Maximum Cited Publications 98 Publications Verification BMN-673; LT-673	PARP	Cancer
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-16291

APTO-253 20+ Cited Publications LOR-253; LT-253	c-Myc KLF Apoptosis	Inflammation/Immunology Cancer
APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor . APTO-253 has antiarthritic activity .

HY-N6607

Tryptanthrin 5+ Cited Publications	Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-111361

FN-1501 2 Publications Verification LT-171-861	CDK FLT3	Cancer
FN-1501 is a potent inhibitor of FLT3 and CDK, with IC₅₀s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.

HY-10037

Quiflapon 1 Publications Verification MK-591	FLAP Apoptosis	Inflammation/Immunology
Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC₅₀ of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active Leukotriene biosynthesis (LT) inhibitor, shows IC₅₀ values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis .

HY-P11099

Cys-LT7	Transferrin Receptor	Neurological Disease Cancer
Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .

HY-132828

Odatroltide LT3001; DHDMIQK(KAP)	P-selectin	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities .

HY-P99459

Baminercept 2 Publications Verification BG 9924; TT-47	TNF Receptor CXCR	Inflammation/Immunology
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .

HY-P991400

GSK1995057	TNF Receptor Apoptosis Interleukin Related NF-κB JNK p38 MAPK	Inflammation/Immunology
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and *LT-α, and does not interfere with TNFR2* signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .

HY-16106A

(8R,9S)-Talazoparib (8R,9S)-BMN-673; (8R,9S)-LT-673	PARP	Cancer
(8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an PARP1 inhibitor, with an IC₅₀ of 144 nM .

HY-124801

ABMA 1 Publications Verification	Flavivirus Dengue Virus Bacterial Parasite	Infection
ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activity .

HY-130622

LT052 1 Publications Verification	Epigenetic Reader Domain	Inflammation/Immunology
LT052 is a highly selective BET BD1 inhibitor with an IC₅₀ of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC₅₀=12.130 μM). LT052 has anti-inflammatory?activity and can be used for acute gout arthritis research .

HY-P99318

Sonepcizumab LT 1009; Anti-Human S1P Recombinant Antibody	LPL Receptor	Cancer
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .

HY-123984

LTβR-IN-1	NF-κB	Metabolic Disease
LTβR-IN-1 (Compound 919278) is a potent, selective lymphotoxin β receptor (LTβR) inhibitor. LTβR-IN-1 also selectively inhibits the nuclear translocation of p52 depended on TNF12A, instead of the nuclear translocation of p65 mediated by TNF-α receptor. LTβR-IN-1 regulates the NF-kB signaling pathway IN a ligand-independent manner .

HY-139997

DDC-01-163	PROTACs EGFR	Cancer
DDC-01-163 is an allosteric PROTAC degrader targeting EGFR. DDC-01-163 is dependent on the ubiquitin–proteasome system. DDC-01-163 can selectively inhibit the proliferation of L858R/T790M (L/T) mutant Ba/F3 cells. DDC-01-163 is effective against Osimertinib (HY-15772)-resistant cells with L/T/C797S and L/T/L718Q EGFR mutations. DDC-01-163 exhibits enhanced anti-proliferative activity against L858R/T790M EGFR-Ba/F3 cells when combined with the ATP-site EGFR inhibitor Osimertinib. DDC-01-163 can be used for the study of non-small cell lung cancer .

HY-121900

LT175	PPAR	Metabolic Disease Endocrinology
LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ(hPPARα:EC₅₀=0.22 μm; mPPARα:EC₅₀=0.26 μm; hPPARγ:EC₅₀=0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties .

HY-164768

LT25	Integrin	Cancer
LT25 (compound 17) is a agonist of α5β1 integrin with EC₅₀ value of 9.9 nM .

HY-N6607R

Tryptanthrin (Standard)	Reference Standards Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
Tryptanthrin (Standard) is the analytical standard of Tryptanthrin. This product is intended for research and analytical applications. Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-16106S

Talazoparib-13C,d4 BMN-673-¹³C,d₄; LT-673-¹³C,d₄	Isotope-Labeled Compounds	Others
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-16106S1

Talazoparib-d4 BMN-673-d₄; LT-673-d₄	Isotope-Labeled Compounds PARP	Cancer
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-179407

LT-104A	Phosphodiesterase (PDE)	Inflammation/Immunology
LT-104A is a potent PDE4 inhibitor that elevates intracellular cAMP levels (EC₅₀ = 1.9 μM) and inhibits PDE4D3 activity (IC₅₀ = 9.3 μM). LT-104A activates the cAMP-PKA-CREB anti-inflammatory signaling pathway and suppresses NF-κB-related gene expression (Il1b and Nos2). LT-104A can be used for inflammation-related disease research .

HY-105483

MDL 43291	Leukotriene Receptor	Inflammation/Immunology
MDL 43291 is a competitive leukotriene (LT) receptor antagonist. MDL 43291 antagonize LTD4 and LTE4 with pA2 of 6.7. MDL 43291 does not antagonize histamine, carbachol or substance P. MDL 43291 can be used for the researches of inflammation and immunology, such as asthma .

HY-176735

FLT3/IRAK4-IN-1	IRAK FLT3 Apoptosis	Cancer
FLT3/IRAK4-IN-1 is a selective FLT3/IRAK4 inhibitor with the remarkable activity towards FLT3-WT (IC₅₀ = 1.95 nM), FLT3-D835Y (IC₅₀ = 3.22 nM) and IRAK4 (IC₅₀ = 53.72 nM). LT3/IRAK4-IN-1 has relatively low toxicity to normal bone marrow cells, can effectively promote cell apoptosis, and has the potential to overcome drug resistance. FLT3/IRAK4-IN-1 can be used for research on acute myeloid leukemia (AML) .

HY-127110

AK106-001616	Phospholipase	Others Neurological Disease Inflammation/Immunology
AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC₅₀=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis .

HY-162378

LT-630	HDAC	Inflammation/Immunology
LT-630 is a HDAC6 inhibitor. LT-630 ameliorates liver injury by reducing oxidative damage .

HY-173466

LT-188A	G protein-coupled Bile Acid Receptor 1	Metabolic Disease Inflammation/Immunology
LT-188A is a potent TGR5 agonist with an EC₅₀ of 23 μM. LT-188A decreases the levels of inflammatory mediators in macrophages .

HY-155594

LT-540-717	FLT3	Cancer
LT-540-717 (compound 32) is a potent FLT3 inhibitor (IC₅₀=0.62 nM) with antiproliferative activity. LT-540-717 also inhibits several acquired FLT3 mutations, FLT3 (ITD, D835V), FLT3 (ITD, F691L), FLT3 (D835Y) and FLT3 (D835V). LT-540-717 has potential to be an anti-AML agent .

HY-139619

LT-850-166	FLT3	Cancer
LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations.

HY-P991310

Lpathomab LT3015; LT-3000	LPL Receptor	Neurological Disease Cancer
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-163761

LT166	CCR	Others
LT166 is a fluorescent ligand for CC chemokine receptor 1 (CCR1) with a K_D of 1.90 μM .

HY-151619

sEH inhibitor-12	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-12 (compound 34) is a sEH inhibitor with an IC₅₀ value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC₅₀ value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation .

HY-19675

Naproxen etemesil LT-NS 001; MX 1094	COX	Inflammation/Immunology
Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC₅₀s of 8.72 and 5.15 μM, respectively in cell assay.

HY-123571

CP-199330	Leukotriene Receptor	Inflammation/Immunology
CP-199330 is a potent and orally active cysteinyl LT1 receptor antagonist .

HY-RS07868

LTA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LTA Human Pre-designed siRNA Set A contains three designed siRNAs for LTA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LTA Human Pre-designed siRNA Set A LTA Human Pre-designed siRNA Set A

HY-16291A

APTO-253 hydrochloride LOR-253 hydrochloride; LT-253 hydrochloride	c-Myc	Inflammation/Immunology
APTO-253?(LOR-253) hydrochloride is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253?hydrochloride mediates anticancer activity via induction of Kruppel-like factor 4?(KLF4)?tumor suppressor. APTO-253?hydrochloride exhibits antiarthritic activity .

HY-14687

(rac)-Talazoparib (rac)-BMN-673; (rac)-LT-673	PARP	Cancer
(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is the orally active inhibitor for PARP1/2 with K_i of 1.2 nM and 0.87 nM. (rac)-Talazoparib inhibits cellular PARylation with an EC₅₀ of 2.51 nM. (rac)-Talazoparib causes the accumulation of DNA damage, inhibits proliferation of BRCA1/2-mutated MX-1 cell and Capan-1 cell with IC₅₀ of 0.3 nM and 5 nM. (rac)-Talazoparib exhibits antitumor efficacy in mouse models .

HY-161709

FLT3/CDKs ligand-1	Ligands for Target Protein for PROTAC FLT3 CDK	Cancer
FLT3/CDKs ligand-1 (Compound 14) is a ligand for target protein, which promotes the degradation of cyclin-dependent kinase (CDK) and the FMS-like tyrosine kinase 3 (FLT3), inhibits FLT3/CDK related proliferations and survivals of leukemia cells. LT3/CDKs ligand-1 can be used for synthesis of PROTAC FLT3/CDKs degrader-1 (HY-161708) .

HY-151617

sEH inhibitor-11	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-11 (compound 35) is a sEH inhibitor with an IC₅₀ value of 0.3 μM. sEH inhibitor-11 can be used for the research of inflammation .

HY-19161

Bay-X-7195	Leukotriene Receptor	Inflammation/Immunology
Bay-X-7195 is a CYS leukotriene 1 receptor (CYS LT1) antagonist. Bay-X-7195 shows an antagonistic action to LTD4-induced bronchoconstriction in vitro and in vivo. Bay-X-7195 can be used foe the study of allergic and asthmatic .

HY-RS07869

Lta Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Lta Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lta gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lta Mouse Pre-designed siRNA Set A Lta Mouse Pre-designed siRNA Set A

HY-141467S

Propionyl CoA-d5	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Propionyl CoA-d₅ is the deuterium labeled Propionyl CoA (HY-141467). Propionyl CoA serves as a common intermediate in the catabolic pathways of 1,2-propanediol and propionate in Salmonella enterica serovar Typhimurium LT2, and also functions as a precursor for 2-methylcitrate. Propionyl CoA is utilized as a substrate for the 2-methylcitrate synthase (PrpC) enzyme to synthesize 2-methylcitrate .

HY-19042

YM-16638 YM 638	Leukotriene Receptor	Inflammation/Immunology
YM-16638 is an orally active leukotriene (LT) antagonist. YM-16638 can inhibit the production of LTC₄, LTD₄, and LTE₄ in guinea pig trachea, with IC₅₀ values of 0.05 μM, 0.16 μM, and 0.096 μM, respectively. YM-16638 has a dose-dependent inhibitory effect on antigen-induced early and late respiratory responses in allergic sheep .

HY-14162

AM103 free acid	FLAP	Inflammation/Immunology
AM103 (free acid) is a selective FLAP inhibitor that can block the first step of the LT pathway, which is 5-LO activation. AM103 (free acid) can inhibit the production of LTB₄ and cysteinyl leukotrienes (CysLT). AM103 (free acid) has anti-inflammatory activity in a mouse model of chronic lung inflammation and can extend the survival time of mice injected with platelet-activating factor. AM103 (free acid) can be used for research on respiratory diseases such as asthma .

HY-173409

AR antagonist 11	Androgen Receptor Ser/Thr Protease	Inflammation/Immunology
AR antagonist 11 (Compound c2) is a selective AR antagonist with an IC₅₀ of 0.019 μM. AR antagonist 11 is also effective against AR ^F877L/T878A mutant (IC₅₀: 1.03 μM). AR antagonist 11 inhibits LNCaP cell proliferation and reduces PSA protein expression (IC₅₀: 0.54 μM). AR antagonist 11 can be used for research of prostate cancer (PCa) .

HY-10037R

Quiflapon (Standard) MK-591 (Standard)	Reference Standards FLAP Apoptosis	Inflammation/Immunology
Quiflapon (Standard) is the analytical standard of Quiflapon. This product is intended for research and analytical applications. Quiflapon (MK-591) is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50?of 1.6 nM in a FLAP binding assay. Quiflapon is also a potent and orally active?Leukotriene biosynthesis (LT)?inhibitor, shows IC50?values of 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively. Quiflapon induces cell apoptosis .

HY-155408

ALR-27	FLAP	Inflammation/Immunology
ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes .

HY-148302

LT-626	PARP	Cancer
LT-626 is a potent PARP inhibitor with an IC₅₀ of 1.60 nM. LT-626 inhibits cellular PAR synthesis with an EC₅₀ of 17.9 nM and shows enhanced cytotoxicity in colorectal cancer cells harboring MRE11 mutations. LT-626 exhibits synergistic effects with Cisplatin (HY-17394), Oxaliplatin (HY-17371), and SN-38 (HY-13704) in colorectal cancer cells. LT-626 can be used for colorectal research .

HY-159922

AR antagonist 9	Androgen Receptor	Cancer
AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC₅₀ value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC₅₀ = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against *AR_F876L/T877A* and AR_W741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .

HY-117947

(R)-OR-S1	Histone Methyltransferase	Cancer
(R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.

HY-D3291

IR 680LT Maleimide	Fluorescent Dye	Others
IR 680LT Maleimide is a near-infrared low-band fluorescence dye, composed of the IR 680LT dye core and maleimide groups. IR 680LT Maleimide is used for specifically labeling biologically active molecules containing sulfhydryl groups (Ex/Em = 679 nm/694 nm).

Cat. No.	Product Name	Type

HY-D3291

IR 680LT Maleimide	Fluorescent Dyes
IR 680LT Maleimide is a near-infrared low-band fluorescence dye, composed of the IR 680LT dye core and maleimide groups. IR 680LT Maleimide is used for specifically labeling biologically active molecules containing sulfhydryl groups (Ex/Em = 679 nm/694 nm).

HY-D3272

IR 680LT NHS ester	Fluorescent Dyes
IR 680LT NHS ester is a fluorescent dye with an NHS ester moiety, which can be used to label antibodies, proteins, etc (Ex/Em = 675/694 nm) .

Cat. No.	Product Name	Target	Research Area

HY-P11099

Cys-LT7	Transferrin Receptor	Neurological Disease Cancer
Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .

HY-132828

Odatroltide LT3001; DHDMIQK(KAP)	P-selectin	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99459

Baminercept 2 Publications Verification BG 9924; TT-47	TNF Receptor CXCR	Inflammation/Immunology
Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .

HY-P991400

GSK1995057	TNF Receptor Apoptosis Interleukin Related NF-κB JNK p38 MAPK	Inflammation/Immunology
GSK1995057 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK1995057 selectively binds to TNFR1, blocks the binding of TNF-α and *LT-α, and does not interfere with TNFR2* signaling. GSK1995057 inhibits the activation of NF-κB, JNK and MAPK pathways, alleviates apoptosis (apoptosis) and inflammatory responses (inhibiting IL-1β, IL-6, IL-10, TNF-α), and prevents viability loss of human nucleus pulposus cells. GSK1995057 inhibits the expression of cytokines and neutrophil adhesion molecules in human pulmonary microvascular endothelial cell monolayers, and reduces inflammatory responses and lung injury symptoms in non-human primates. GSK1995057 forms complexes with HAVH autoantibodies, thereby activating TNFR1 and triggering the release of cytokines and IL-8 in human cells. GSK1995057 can be used in research related to intervertebral disc degeneration and acute lung injury .

HY-P99318

Sonepcizumab LT 1009; Anti-Human S1P Recombinant Antibody	LPL Receptor	Cancer
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .

HY-P990034

Pateclizumab 1 Publications Verification MLTA3698A; RG7415; PRO283698	Inhibitory Antibodies	Inflammation/Immunology
Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis .

HY-P991310

Lpathomab LT3015; LT-3000	LPL Receptor	Neurological Disease Cancer
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992151

Sphingomab LT1002	LPL Receptor Interleukin Related	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Sphingomab (LT1002) is a mouse-derived IgG1 κ monoclonal antibody and also an inhibitor targeting S1P, with high affinity for S1P and a K_d value of 0.03 ± 0.002 nM. Sphingomab blocks S1P-mediated IL-8 release in ovarian cancer cells. Sphingomab exhibits anti-angiogenic activity in a mouse model of choroidal neovascularization. Sphingomab reduces peripheral blood lymphocyte counts. Sphingomab can be used in the research of ovarian cancer and age-related macular degeneration .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6607

Tryptanthrin 5+ Cited Publications	Alkaloids Classification of Application Fields Polygonaceae Plants Polygonum tinctorium Ait. Inflammation/Immunology Disease Research Fields Indole Alkaloids Source Classification	Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related
Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-N6607R

Tryptanthrin (Standard)	Alkaloids Structural Classification Polygonaceae Plants Polygonum tinctorium Ait. Indole Alkaloids Source Classification	Reference Standards Leukotriene Receptor NO Synthase NF-κB COX TNF Receptor Interleukin Related
Tryptanthrin (Standard) is the analytical standard of Tryptanthrin. This product is intended for research and analytical applications. Tryptanthrin is an indole quinazoline that could be an alkaloid from indigo-bearing plants. Tryptanthrin is a potent and orally active cellular Leukotriene (LT) biosynthesis inhibitor. Tryptanthrin has anticancer activity. Tryptanthrin suppresses the expression levels of NOS1, COX-2, and NF-κB and regulates the expression levels of IL-2, IL-10, and TNF-α .

HY-178898

7-Oxogedunin	Structural Classification Natural Products Swietenia humilis Zucc. Plants Meliaceae Source Classification	NOD-like Receptor (NLR) Caspase Insecticide Ser/Thr Protease Pyroptosis
7-Oxogedunin (Compound 7DG; Compound 16) is a small molecule that protects macrophages from cell pyroptosis induced by anthrax lethal toxin (LT). Its target is protein kinase R (PKR). 7-Oxogedunin can widely inhibit the assembly of various inflammasomes (NLRP1 and NLRP3) and the activation of caspase-1 by inhibiting the kinase-independent function of PKR. 7-Oxogedunin has growth inhibitory activity on European corn borer larvae. 7-Oxogedunin can be used for LT toxicity inhibition and pest control research .

Species:	Human (6) Mouse (2) Cynomolgus (1)
Tag:	His (6) Tag Free (1) Avi (1) Fc (2) Flag (1)
Source:	HEK293 (4) Sf9 insect cells (2) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P700419

	TNF-beta/TNFSF1 Protein, Human (HEK293, His) LTA; lymphotoxin alpha (TNF superfamily, member 1); LT; TNFB; TNFSF1; lymphotoxin alpha; OTTHUMP00000165897; tumor necrosis factor beta; Tumor necrosis factor ligand superfamily member 1; TNF-beta; LT-alpha	Human	HEK293
	TNF-β protein acts as a homotrimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM. TNF-beta/TNFSF1 Protein, Human (HEK293, His) is the recombinant human-derived TNF-beta/TNFSF1 protein, expressed by HEK293 , with N-6*His labeled tag.

HY-P700154AF

	Animal-Free TNF-beta/TNFSF1 Protein, Human (His) Lymphotoxin-Alpha; LT-Alpha; TNF-beta; Tumor Necrosis Factor Ligand Superfamily Member 1; LTA; TNFB; TNFSF1	Human	E. coli
	TNF-β protein acts as a homotrimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM. Animal-Free TNF-beta/TNFSF1 Protein, Human (His) is the recombinant human-derived animal-FreeTNF-beta/TNFSF1 protein, expressed by E. coli , with N-His labeled tag. This product is for cell culture use only.

HY-P700228AF

	Animal-Free TNF-beta/TNFSF1 Protein, Mouse (His) TNFSF1B; Lymphotoxin-alpha (LT-α); LTalpha; LTx; TNF-be; TNFSF1; Tnf; Tnfb; Tnfsf; Tnfsf1b; Tnlg1e; hlb38; hlb382; lymph	Mouse	E. coli
	The animal-free TNF beta protein acts as a homotrimeric cytokine that binds TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM.Animal-Free TNF-beta/TNFSF1 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeTNF beta protein, expressed by E.coli , with N-His labeled tag.This product is for cell culture use only.

HY-P700612

	TNF-beta/TNFSF1 Protein, Human (Biotinylated, HEK293, His-Avi) LTA; lymphotoxin alpha (TNF superfamily, member 1); LT; TNFB; TNFSF1; lymphotoxin alpha; OTTHUMP00000165897; tumor necrosis factor beta; Tumor necrosis factor ligand superfamily member 1; TNF-beta; LT-alpha	Human	HEK293
	TNF-β protein acts as a homotrimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM. TNF-beta/TNFSF1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived TNF-beta/TNFSF1 protein, expressed by HEK293 , with N-Avi, N-6*His labeled tag.

HY-P7304

	TNF-beta/TNFSF1 Protein, Human rHuTNF-β; TNF-β; TNFSF1; Lymphotoxin-alpha	Human	E. coli
	TNF-β (tumor necrosis factor β) also called lymphotoxin-α (LT-α), a member of the tumor necrosis factor superfamily, is a cytokine produced by lymphocytes. TNF-β activates the NF-κB signaling pathway, inducing cancer cell proliferation, invasion. TNF-β up-regulates genes connected with metastasis, promotes epithelial-to-mesenchymal-transition, stimulates its own expression. TNF-β mediates a large variety of inflammatory, immunostimulatory, and antiviral responses. TNF-beta/TNFSF1 Protein, Human is a recombinant protein consisting of 158 amino acids (L35-L205) and is produced in E. coli.

HY-P76482

	TNFSF3/Lymphotoxin Beta Protein, Cynomolgus (sf9, His) Lymphotoxin-beta; LT-beta; Tumor necrosis factor C; TNF-C; LTB; TNFSF3	Cynomolgus	Sf9 insect cells
	Lymphotoxin Beta (LT-beta) also known as TNFSF3, is a type II transmembrane glycoprotein of the TNF family. Lymphotoxin Beta binds to LTα to form membrane-anchored heterotrimers that activate canonical/noncanonical nuclear factor-κB (NF-κB) signaling thus inducing chemokine, cytokine or adhesion molecule expression, cell proliferation and cell survival. Lymphotoxin Beta also shows anti-inflammatory, anti-cancer activity. Lymphotoxin Beta regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. TNFSF3/Lymphotoxin Beta Protein, Cynomolgus (sf9, His) is a recombinant protein with a N-Terminal His label, It consists of 197 amino acids (Q49-G244) and is produced in Sf9 insect cells.

HY-P703107

	LT4R1 Protein, Human (sf9, Flag, His) BLT; BLT1; BLTR; CMKRL1; GPR16; P2RY7	Human	Sf9 insect cells
	LT4R1 Protein, Human (sf9, Flag, His) is the recombinant human-derived LT4R1, expressed by sf9 insect cells , with His, Flag labeled tag. ,

HY-P704240

	AF488-Labeled CD3 epsilon Protein, Mouse (HEK293, Fc) FLJ18683; LT3E; LTCRE; LCD3E; LCD3-epsilon	Mouse	HEK293

HY-P704408

	TNF-beta/TNFSF1 Protein, Human (144a.a, HEK293, hFc) Lymphotoxin-Alpha; LT-Alpha; TNF-beta; Tumor Necrosis Factor Ligand Superfamily Member 1; LTA; TNFB; TNFSF1	Human	HEK293
	TNF-β protein acts as a homotrimeric cytokine that binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR, and TNFRSF14/HVEM. TNF-beta/TNFSF1 Protein, Human (144a.a, HEK293, hFc) is the recombinant human-derived TNF-beta/TNFSF1 protein, expressed by HEK293, with N-hFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-16106S1

Talazoparib-d4
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-141467S

Propionyl CoA-d5
Propionyl CoA-d₅ is the deuterium labeled Propionyl CoA (HY-141467). Propionyl CoA serves as a common intermediate in the catabolic pathways of 1,2-propanediol and propionate in Salmonella enterica serovar Typhimurium LT2, and also functions as a precursor for 2-methylcitrate. Propionyl CoA is utilized as a substrate for the 2-methylcitrate synthase (PrpC) enzyme to synthesize 2-methylcitrate .

Host:	Mouse (4) Rabbit (3)
Reactivity:	Human (5) Mouse (4) Species independent (2)
Application:	IHC-P (2) ICC/IF (2) IP (2) WB (7) FC (4) ELISA (4)
Isotype:	IgG (3) IgG1 (2) IgG2a (2)
Conjugation:	Non-conjugated (7) Biotin (1) AF 488 (1)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83511

	SV40 T Antigen Antibody (YA3256) 1 Publications Verification Large T antigen; LT; LT-AG	WB, ICC/IF, IP	Species independent
	SV40 T Antigen Antibody (YA3256) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SV40 T Antigen.

HY-P83511A

	SV40 T Antigen Antibody (YA3256)(PBS only) Large T antigen; LT; LT-AG	WB, ICC/IF, IP	Species independent
	SV40 T Antigen Antibody (YA3256) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SV40 T Antigen.

HY-P84288

	LTBR Antibody (YA3985) TNFCR; TNFR3; D12S370; TNFR-RP; TNFRSF3; TNFR2-RP; LT-BETA-R; TNF-R-III	WB, FC, ELISA	Human, Mouse
	LTBR Antibody (YA3985) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to LTBR.

HY-P84288A

	LTBR Antibody (YA3985)(PBS only) TNFCR; TNFR3; D12S370; TNFR-RP; TNFRSF3; TNFR2-RP; LT-BETA-R; TNF-R-III	WB, FC, ELISA	Human, Mouse
	LTBR Antibody (YA3985) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to LTBR.

HY-P84235

	SMARCA1 Antibody (YA3932) SWI; ISWI; SWI2; SNF2L; SNF2L1; SNF2LB; SNF2LT; hSNF2L; NURF140	WB, IHC-P, FC, ELISA	Human, Mouse
	SMARCA1 Antibody (YA3932) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SMARCA1.

HY-P83589

	Lymphotoxin alpha Antibody (YA3334) LTalpha; DIF; LT alpha; LTa; Lymphotoxin alpha; TNF B; TNF superfamily member 1; TNF-beta; TNFB; TNFbeta; TNFSF1; TNLG1E	WB	Human
	Lymphotoxin alpha Antibody (YA3334) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lymphotoxin alpha.

HY-P84235A

	SMARCA1 Antibody (YA3932)(PBS only) SWI; ISWI; SWI2; SNF2L; SNF2L1; SNF2LB; SNF2LT; hSNF2L; NURF140	WB, IHC-P, FC, ELISA	Human, Mouse
	SMARCA1 Antibody (YA3932) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SMARCA1.